
IFW

PTO/SB/21 (09-04) MODIFIED

TRANSMITTAL FORM			Application Number:	10/69	10/696,255 October 29, 2003			
			Filing Date:	Octo				
			First Named Inventor:	Kimb				
			Art Unit:	1636				
			Examiner Name:	Unkr				
	ges in this Submission:		_ Attorney Docket Number:		CLFR:228US			
TIBELL ST		-	ENCLOSURES (check all that	apply)				
Fee At Amendme After F Affidat Extension of Express At	Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request		Drawings(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Statement under 37 CFR §3.73(b) Designation of Patent Practitioners Terminal Disclaimer Request for Refund CD, Number CD(s) Landscape Table on CD		After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter			
Information Disclosure Statement Form PTO-1449 References C1-C4 Certified Copy of Priority Documents Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 Declaration(s) Copy of Notice of Missing Parts		Ten			Check in t Authorized to if check insu Deposit according Sequence Paper Cop	ure(s) (please identify below) the amount of \$ to be charged to deposit account fficient or inadvertently omitted bunt number: 50-1212/CLFR:228US Statement by of Sequence Listing Readable Form (CRF)		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm Name	Fulbright & wors	ki, L.L.P.			Customer Number	32425		
Signature	(/)X							
Printed Name	Printed Name David L. Parker			Reg. No. 32,165				
Date April 29, 2005					,			
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being fast while transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS AMEND JENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature								
Typed or Printed Name Day		avid L. Par	ker		Date A	pril 29, 2005		



In re Application of: Kimberly Kline *et al*.

Serial No.: 10/696,255

Filed: October 29, 2003

For: MUTANT p53 PROTEINS AND USES

THEREOF

Group Art Unit: 1636

Examiner: Unknown

Atty. Dkt. No.: CLFR:228US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS AMENDMENT, Commissioner for Patents, P.O. Bo 1450, Alexandria, VA 22313-1450, on the date below:

April 29, 2005

Date

David L. Parker

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the

Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/CLFR:227US.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

David L. Parker

Reg. No. 32,165

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

April 29, 2005

t		6	PEVOL						Page 1 of	
Form P	TO-144	(modified)	NO SOURCE OF	Atty. Docket No. Serial No. CLFR:228US 10/696,255						
		d Publication	Applicants THAUTH	Applicant Kimberly Klin	ne <i>et al</i> .					
		everal sheets if necessa		Filing Date: October 29, 20	003		roup:			
U.	· -				Patent Documents Other Art See Page 1 See Page 1				•	
			U.S. Pat	ent Docume	——— ents	. 18 - 176		·	· · · · · · · · · · · · · · · · · · ·	
Exam. Init.	Ref. Des.	Document Number	Date	Name	Name		Class Sub Class		Filing Date of App.	
	<u> </u>	F	oreign P	atent Docur	nents		J			
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Class Sub T			ranslation Yes/No	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation			
	C1	Bennett, "Mechanisms of p53-induced apoptosis," <i>Biochem. Pharmacol.</i> , 58(7):1089-1095, 1999.			
	C2	O'Connor et al., "Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents," Cancer Res., 57:4285-4300, 1997.			
	C3	Smith et al., "cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype," Oncogene, 18:6063-6070, 1999.			
	C4	Yang et al, "Induction of retinoid resistance in breast cancer cells by overexpression of cJun," Cancer Res. 57:4652-4661, 1997.			

25527809.1

17

_				
EXA	N/I	IN	rD	
LAAA		117		

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.